Hearing disability prevalence and risk factors in two recent national surveysExternalLi CM, Zhao G, Hoffman HJ, Town M, Themann CL.Am J Prev Med. 2018 Jul 18.
Gaps and opportunities: measuring the key population cascade through surveys and services to guide the HIV responseExternalHakim AJ, MacDonald V, Hladik W, Zhao J, Burnett J, Sabin K, Prybylski D, Garcia Calleja JM.J Int AIDS Soc. 2018 Jul;21 Suppl 5:e25119.
The Binding of Isaac: Afterbirth Update 21 2018 no survey
The burden of hepatitis C virus infection in Punjab, India: A population-based serosurveyExternalSood A, Suryaprasad A, Trickey A, Kanchi S, Midha V, Foster MA, Bennett E, Kamili S, Alvarez-Bognar F, Shadaker S, Surlikar V, Garg R, Mittal P, Sharma S, May MT, Vickerman P, Averhoff F.PLoS One. 2018 ;13(7):e0200461.
Responses to hypothetical health scenarios overestimate healthcare utilization for common infectious syndromes: a cross-sectional survey, South Africa, 2012ExternalWong KK, Cohen AL, Martinson NA, Norris SA, Tempia S, von Mollendorf C, Walaza S, Madhi SA, McMorrow ML, Cohen C.BMC Infect Dis. 2018 Jul 25;18(1):344.
Overcoming challenges in school-wide survey administrationExternalRasberry CN, Rose I, Kroupa E, Hebert A, Geller A, Morris E, Lesesne CA.Health Promot Pract. 2018 Jan;19(1):110-118.
Hospital microbiology laboratory practices for Enterobacteriaceae: Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) annual survey, 2015 and 2016ExternalShugart A, Walters MS, Weiner LM, Lonsway D, Kallen AJ.Infect Control Hosp Epidemiol. 2018 Jul 24:1-3.
Cycle of violence among young Kenyan women: The link between childhood violence and adult physical intimate partner violence in a population-based surveyExternalChiang L, Howard A, Gleckel J, Ogoti C, Karlsson J, Hynes M, Mwangi M.Child Abuse Negl. 2018 Jul 21;84:45-52.
HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control studyExternalKempton CL, Payne AB.Blood Adv. 2018 Jul 24;2(14):1750-1755.
Molecular xenomonitoring for Wuchereria bancrofti in Culex quinquefasciatus in two districts in Bangladesh supports transmission assessment survey findingsExternalIrish SR, Al-Amin HM, Paulin HN, Mahmood A, Khan RK, Muraduzzaman AK, Worrell CM, Flora MS, Karim MJ, Shirin T, Shamsuzzaman AK, Tahmina S, Lenhart A, Dubray C.PLoS Negl Trop Dis. 2018 Jul;12(7):e0006574.
An international, web-based, cross-sectional survey examining patients' experiences with different methods of cannabis intake reported that from among a group of 953 self-selected participants, from 31 countries, the vast majority preferred inhalation over other means of administration (e.g. teas, foods, prescription cannabinoid medications) for symptoms such as chronic pain, anxiety, loss of appetite, depression, and insomnia or sleeping disorder. Mean daily doses with smoked or vapourized cannabis were 3.0 g (median for smoked cannabis was 2 g per day; for vapourized cannabis it was 1.5 g per day)Reference 580. With foods/tinctures, mean daily dose was 3.4 g (median was 1.5 g per day), and with teas the mean daily dose was 2.4 g (median 1.5 g). Information regarding cannabinoid potencies of cannabis products (i.e. THC/CBD levels) was not available. Daily frequency of use for smoking was six times per day, whereas with vapourizing it was five times per day. Teas and food/tinctures were used on average twice per day. First onset of effects for smoking were noted on average around 7 min after start of smoking, 6.5 min after start of vapourizing, 29 min after ingestion of tea, and 46 min after ingestion of foods/tinctures. Other data suggests that those patients who use cannabis for medical purposes use up to one gram or less per day. For example, data from the Netherlands suggests the average daily dose of dried cannabis for medical purposes stood at 0.68 g per day (range: 0.65 - 0.82 g per day), whereas information obtained from the Israel medical cannabis program in 2016 suggests the average daily amount used by patients was slightly under 1.5 g (Health Canada personal communication). Canadian market data collected from licensed producers under the Access to Cannabis for Medical Purposes Regulations (ACMPRs) showed that, from April 2017 to March 2018, clients had been authorized by their healthcare practitioners to use, monthly, an average of 2.1-2.5 g/day of dried cannabis. However, since this data is collected per licensed producer, it does not include cases where clients split their authorization into two or more authorizations in order to register with more than one licensed producer at a time or personal production registrations with Health CanadaReference 581. There is no specific data on the average amount of oil authorized by healthcare practitioners since authorized amounts are always in g/day. To fulfill orders for oils, licensed producers equate oil to dried cannabis based on the formulation of their oil products. On average, licensed producers equate 1 g of dried cannabis to 6.6 g of oil. Using this average conversion factor, healthcare practitioners have authorized an equivalent average of 13.9-16.5 g/day of oil.
The purpose of this report is to provide an update on the progress of the Hokkaido Study, summarize recent results, and suggest future directions. In particular, this report provides the latest details from questionnaire surveys, face-to-face examinations, and a collection of biological specimens from children and measurements of their chemical exposures.
Four years have passed since the most recent profile paper. This coincides with the follow-up stage with the shift to pubertal age. Children are not only exposed to environmental chemicals in utero, but also continue to be exposed after birth. Questionnaire survey and face-to-face examination becomes important as for limitation survey. Thus, this report aims to provide an update on the progress of the Hokkaido Study. In particular, this paper focuses on the (1) profiles of the children with further follow-ups until pubertal age, (2) exposure assessments of the children, and (3) summaries of our recent findings. This paper also discusses the importance of longer follow-up periods and future research directions.
While this initial list of Steam Deck compatibility problems is far from a randomly chosen scientific survey, it's still an interesting look at the small issues that are likely to affect some titles when the hardware launches. It will be interesting to see how many "Playable" titles issue updates to achieve full "Verified" status after the Steam Deck is in players' hands.
[13] Deloitte survey: Blockchain reaches beyond financial services with some industries moving faster. Deloitte, Dec. 13, 2016. -deloitte/articles/press-releases/deloitte-survey-blockchain-reaches-beyond-financial-services-with-some-industries-moving-faster.html (accessed Feb. 15, 2018). 2ff7e9595c
Comments